Pages that link to "Q34123595"
Jump to navigation
Jump to search
The following pages link to Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity (Q34123595):
Displaying 50 items.
- Prediction of co-receptor usage of HIV-1 from genotype (Q21090162) (← links)
- Drug-eluting fibers for HIV-1 inhibition and contraception (Q21133885) (← links)
- Hybrid approach for predicting coreceptor used by HIV-1 from its V3 loop amino acid sequence (Q21559666) (← links)
- Allostery at G Protein-Coupled Receptor Homo- and Heteromers: Uncharted Pharmacological Landscapes (Q24633877) (← links)
- HIV-1 entry inhibitors: an overview (Q24645525) (← links)
- Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects (Q24650421) (← links)
- Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent (Q24656023) (← links)
- Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1 (Q24673555) (← links)
- Protease-Activated Receptors and other G-Protein-Coupled Receptors: the Melanoma Connection (Q26744512) (← links)
- Applications of Replicating-Competent Reporter-Expressing Viruses in Diagnostic and Molecular Virology (Q26750838) (← links)
- Maraviroc: a review of its use in HIV infection and beyond (Q26778504) (← links)
- The macrophage: a therapeutic target in HIV-1 infection (Q26823236) (← links)
- Curing a viral infection by targeting the host: the example of cyclophilin inhibitors (Q26828727) (← links)
- Current perspectives on HIV-1 antiretroviral drug resistance (Q26852626) (← links)
- Regulation of G protein-coupled receptors by allosteric ligands (Q26864384) (← links)
- HIV-1 entry inhibitors: recent development and clinical use (Q27003887) (← links)
- HIV: cell binding and entry (Q27008983) (← links)
- G-protein-coupled receptors targeting: the allosteric approach (Q27023311) (← links)
- Decoding protein networks during virus entry by quantitative proteomics (Q27469058) (← links)
- The Conformation and Orientation of a 27-Residue CCR5 Peptide in a Ternary Complex with HIV-1 gp120 and a CD4-Mimic Peptide (Q27670815) (← links)
- Burkholderia oklahomensisagglutinin is a canonical two-domain OAA-family lectin: structures, carbohydrate binding and anti-HIV activity (Q27676767) (← links)
- Structure-Based Design, Synthesis, and Characterization of Dual Hotspot Small-Molecule HIV-1 Entry Inhibitors (Q27678493) (← links)
- Crystal Structures of HIV-1 gp120 Envelope Glycoprotein in Complex with NBD Analogues That Target the CD4-Binding Site (Q27681568) (← links)
- Bioinformatic analysis of HIV-1 entry and pathogenesis (Q27693321) (← links)
- Approved Antiviral Drugs over the Past 50 Years (Q27755387) (← links)
- The design of drugs for HIV and HCV (Q28259321) (← links)
- Access denied? The status of co-receptor inhibition to counter HIV entry (Q28300187) (← links)
- The evolutionary analysis of emerging low frequency HIV-1 CXCR4 using variants through time--an ultra-deep approach (Q28476558) (← links)
- Maraviroc: the evidence for its potential in the management of HIV (Q28476655) (← links)
- An inducible cell-cell fusion system with integrated ability to measure the efficiency and specificity of HIV-1 entry inhibitors (Q28477736) (← links)
- 8-Modified-2'-deoxyadenosine analogues induce delayed polymerization arrest during HIV-1 reverse transcription (Q28477840) (← links)
- Potent host-directed small-molecule inhibitors of myxovirus RNA-dependent RNA-polymerases (Q28478155) (← links)
- Estimating the threshold surface density of Gp120-CCR5 complexes necessary for HIV-1 envelope-mediated cell-cell fusion (Q28478341) (← links)
- Structural insights from binding poses of CCR2 and CCR5 with clinically important antagonists: a combined in silico study (Q28481687) (← links)
- Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model (Q28484915) (← links)
- Analysis of physicochemical and structural properties determining HIV-1 coreceptor usage (Q28488611) (← links)
- The root extract of the medicinal plant Pelargonium sidoides is a potent HIV-1 attachment inhibitor (Q28539308) (← links)
- Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial (Q28552729) (← links)
- A novel small-molecule inhibitor of HIV-1 entry (Q28606625) (← links)
- Virus-host interactomics: new insights and opportunities for antiviral drug discovery (Q28652236) (← links)
- Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected (Q28741704) (← links)
- The biology of CCR5 and CXCR4 (Q29012920) (← links)
- How were new medicines discovered? (Q29616641) (← links)
- Defining the fitness of HIV-1 isolates with dual/mixed co-receptor usage (Q30278577) (← links)
- HIV-1 genetic variation and drug resistance development. (Q30354857) (← links)
- Ligand- and mutation-induced conformational selection in the CCR5 chemokine G protein-coupled receptor (Q30366048) (← links)
- Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applications (Q30366071) (← links)
- Reliable genotypic tropism tests for the major HIV-1 subtypes (Q30372085) (← links)
- Appreciating HIV type 1 diversity: subtype differences in Env. (Q30375834) (← links)
- Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor. (Q30378764) (← links)